Renal cell carcinoma growing into the renal pelvis and mimicking transitional cell carcinoma: A case report and literature review

Li, Yifan; Ding, Yu; Chen, Duqun; Yu, Zuhu; Gui, Yaoting; Yang, Shangqi; Lai, Yongqing

doi:10.3892/ol.2015.2898

Cited by 11 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 , 28 Due to the hollow structure of the renal pelvis, pelvicalyceal invasion is easier for localized RCC originating from the marginal parenchyma surrounding the renal pelvis. 29 , 30 The anatomic features of endophytic growth, proximity to the collecting system, and central location relative to the polar lines observed in our study might explain the tendency of pelvicalyceal invasion in the Xp11.2 translocation RCC group. RCCs with pelvicalyceal invasion were possibly mistaken for transitional cell carcinoma, even after contrast-enhanced CT, CT urography, or magnetic resonance imaging (MRI).…”

Section: Discussionmentioning

confidence: 52%

Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China

Liu

Shi

et al. 2020

Ann Surg Oncol

View full text Add to dashboard Cite

Purpose To evaluate the oncologic efficacy and feasibility of nephron-sparing surgery (NSS) in adult Xp11.2 translocation renal cell carcinoma (RCC). Patients and Methods Seventy patients with Xp11.2 translocation RCC and 273 with conventional RCC from five institutions in Nanjing were retrospectively studied. All patients were older than 18 years and were categorized into clinical T1 (cT1) stage using preoperative imaging. Using the preoperative imaging and electronic medical records, anatomical and pathological features were collected and analyzed. Results Among patients with Xp11.2 translocation RCC, 18/36 (50.0%) with cT1a and 12/34 (35.3%) with cT1b tumors underwent NSS. The respective proportions in the conventional RCC group were 121/145 (83.4%) and 93/128 (72.7%). Among cT1a tumors, the Xp11.2 translocation RCCs tended to be adjacent to the collecting system, sinus, and axial renal midline compared with conventional RCCs. Patients with Xp11.2 translocation RCCs who underwent NSS had comparable progression-free survival (PFS) and overall survival to radical nephrectomy (RN) patients ( P > 0.05). Among cT1b tumors, surgical margin positivity and pelvicalyceal, vascular, and region lymphatic involvement were more likely to occur in the Xp11.2 translocation RCCs ( P < 0.05). Patients with Xp11.2 translocation RCC who underwent RN had a more favorable PFS than those who underwent NSS ( P = 0.048). However, multivariate analysis of PFS did not identify surgical method as a risk factor ( P = 0.089). Conclusions Among adults with Xp11.2 translocation RCC, NSS can be an alternative for patients with cT1a tumor but should be performed with more deliberation in patients with cT1b tumors. Electronic supplementary material The online version of this article (10.1245/s10434-020-08813-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 52%

Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China

Liu

Shi

et al. 2020

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Bata et al (13), concluded that using multiple small ROIs was valuable for distinguishing IRM from IUC. However, based on one case and literature review, Li et al (14) reported that imaging results of hypovascular RCC were indistinguishable from IUC. Han et al (15), attempted to evaluate the potential systemic inflammatory markers to differentiate between infiltrative RCC and infiltrative UCs.…”

Section: Discussionmentioning

confidence: 99%

Intrarenal urothelial cancers confused as infiltrative renal masses: Report of 22�cases and literature review

Ding

Jia

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Distinguishing infiltrative renal masses (IRMs) from intrarenal urothelial cancers (IUCs) is critically important, but may be challenging for any radiologist or urologist. The present study aimed to summarize the clinical, imaging and pathological characteristics of IRM, which were postoperatively confirmed as IUC. The analysis was performed using the records of 22 patients who were preoperatively diagnosed with IRM but the results of percutaneous biopsies or postoperative pathological analyses led to diagnoses of urothelial cancers (UCs) from January 2011 to December 2017. The demographic data, computed tomography (CT) imaging features and pathological characteristics were evaluated. The present study also reviewed the literature concerning the IRM and IUC. The mean age of patients was 62 years and 86.4% of them were >55 years. The sex and tumor side distributions were equal. Hematuria and/or flank pain were observed in 86.4% of patients. All patients exhibited endophytic solid renal masses with unclear tumor boundaries on CT images. The kidneys of 81.8% of patients maintained their normal shape while mild alternations were observed in 18.2% of cases. A total of 81.8% of patients maintained the reniform shape and 18.2% exhibited mild contour change. Of all patients, all tumors exhibited less or equal attenuation on unenhanced CT images and they were mildlyimproved on enhanced CT. A total of 6 cases were confirmed by biopsy, when patients underwent laparoscopic nephroureterectomy instead of radical nephrectomy. The remaining 16 patients underwent laparoscopic nephrectomy but the postoperative pathological diagnoses revealed the presence of UCs. All postoperatively confirmed cancers were stages T3 and T4 (62.5 and 37.5%, respectively). UCs should be suspected in middle aged or elderly middle-elderly patients presenting renal masses with endophytic solid unclear tumor boundary on unenhanced and slightly enhanced CT images, accompanied with hematuria and/or flank pain. Preoperative biopsy is preferred for complicated cases.

show abstract

“…Renal cell carcinoma (RCC), the malignant tumors consisting of renal parenchyma and renal pelvis [ 1 ], accounts for 90% of the renal malignancies [ 2 ]. Its incidence rate varies with territories and genders; for example, males are approximately twice more likely to suffer from RCC than females [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-203 inhibits epithelial-mesenchymal transition, migration, and invasion of renal cell carcinoma cells via the inactivation of the PI3K/AKT signaling pathway by inhibiting CAV1

Han

Wang

2020

Cell Adhesion & Migration

View full text Add to dashboard Cite

The present study aimed to evaluate the underlying mechanism of microRNA-203 (miR-203) in renal cell carcinoma (RCC) involving the PI3K/AKT signaling pathway. The results revealed downregulated miR-203 and upregulated CAV1 in RCC tissues. Upregulated miR-203 and downregulated CAV1 increased E-cadherin expression and cell apoptosis, decreased β-catenin and N-cadherin expression and cell proliferation, migration and invasion, and blocked cell cycle entry. CAV1, a target gene of miR-203, decreased by up-regulated miR-203, and silencing CAV1 led to the inactivation of PI3K/AKT signaling pathway. In conclusion, our findings suggested that miR-203-mediated direct suppression of CAV1 inhibits EMT of RCC cells via inactivation of the PI3K/AKT signaling pathway.

show abstract

Renal cell carcinoma growing into the renal pelvis and mimicking transitional cell carcinoma: A case report and literature review

Cited by 11 publications

References 14 publications

Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China

Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China

Intrarenal urothelial cancers confused as infiltrative renal masses: Report of 22�cases and literature review

MicroRNA-203 inhibits epithelial-mesenchymal transition, migration, and invasion of renal cell carcinoma cells via the inactivation of the PI3K/AKT signaling pathway by inhibiting CAV1

Contact Info

Product

Resources

About